Viral Vector Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030

Viral Vector Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030

Viral Vector Manufacturing Market By Type (Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, And Others), By Application (Gene Therapy, Cell Therapy, And Vaccines), By End-User (Research Organizations, Biotech And Pharmaceutical Companies, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising popularity of gene and cell therapy and increasing incidences of epidemics and pandemics

The global viral vector manufacturing market was valued at USD 696.17 million in 2023, growing at a CAGR of 19.22% during the forecast period from 2024 to 2030 to reach USD 1,995.43 million by 2030. The demand for viral vector manufacturing is primarily being boosted by the rising cases of serious genetic disorders such as spinal muscular atrophy, hemophilia, retinitis pigmentosa, and others, the rising incidence for different cancer types, increasing popularity and research on gene and cell therapy, and growing concern over sudden occurrence of epidemics and pandemics are further contributing in the overall growth of the viral vector manufacturing market during the forecast period from 2024-2030.

Viral Vector Manufacturing Market Dynamics:

The increasing number of individuals with genetic disorders who are provided with treatment in form of gene and cell therapy via the utilization of viral vectors is the major factor driving the growth of the viral vector manufacturing market. As per the report published by the World Federation of Hemophilia 2022, globally about 347,026 people were reported to be suffering from bleeding disorders in 2020. As per the same source in 2020, nearly around 209,614 people had hemophilia which includes 165,379 cases of hemophilia A, 33,076 cases of hemophilia B, and 11,159 cases of hemophilia type unknown or type not reported.

The above-mentioned source further stated that 84,197 were reported to have Von Willebrand disease and 53,215 people were suffering from other bleeding disorders across the world in 2020.

Also, owing to various advantages such as high gene transduction efficiency, precise delivery of genes to target cells, induction of robust immune responses, and increased cellular immunity among others offered by viral vectors, they are considered an attractive and appropriate vehicle for cancer therapy which is crucial in managing the rising incidence of different cancer types such as blood cancer, bladder cancer, and others. For instance, the data published by Global Cancer Observatory 2022 says that globally around 544,352 cases of Non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. Kymriah by Novartis AG is a lentiviral vector-based gene therapy treatment and the first chimeric antigen receptor (CAR) T cell immunotherapy. Kymriah is approved by the US Food and Drug Administration and is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma.

However, biosafety issues associated with viral vectors and challenges associated with the manufacturing of viral vectors may restrict the growth of the overall viral vector manufacturing market.

The COVID-19 pandemic had a positive impact on the market for viral vector manufacturing. Due to the surge in the number of patients with COVID-19, the number of biotech and pharmaceutical companies backed by the government and other prominent organizations across the world were highly focused on developing solutions in form of vaccines against COVID-19. Later, companies like AstraZeneca and Johnson and Johnson developed COVID-19 vaccines that involved the usage of viral vectors. Apart from these, many other companies are largely involved in the development of viral vector-based vaccines for various other indications. Nevertheless, the viral vector manufacturing market is expected to witness positive growth in the upcoming years.

Viral Vector Manufacturing Market Segment Analysis:

Viral vector manufacturing market by Type (Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, and Others), By Application (Gene Therapy, Cell Therapy, and Vaccines), By End-User (Research Organizations, Biotech And Pharmaceutical Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the vector type segment of the viral vector manufacturing market, the adenoviral vectors category is expected to amass a significant revenue share in the year 2023. This can be attributed to the advantages and applications associated with adenovirus vectors.

Adenoviral vectors have many advantages over other viral vectors, including a wide range of tissue tropism, a well-characterized genome, ease of genetic manipulation, acceptance of large transgene DNA insertions that can be up to 8 kilobases, inherent adjuvant properties, capacity to incite robust transgene-specific T cell and antibody responses, non-replicative host nature, and simplicity of large-scale production.

Adenovirus is known for its high transduction efficiency. They facilitate a high level of gene expression by delivering multiple copies of the genome into one host cell. These can transduce both dividing and non-dividing cells.

Adenoviruses are mostly preferred as gene therapy vectors because the virions are taken up efficiently by cells in vivo. Also, the vaccines derived from adenoviruses that are used in humans are said to have no reported side effects. AstraZeneca's COVID-19 Vaccine and Janssen's (Johnson & Johnson) COVID-19 vaccine are based on an adenoviral vector.

Therefore, considering the advantages associated with adenoviral vectors and their growing usage, this category is expected to generate considerable revenue thereby pushing the overall growth of the global viral vector manufacturing market during the forecast period.

North America is expected to dominate the overall Viral Vector Manufacturing Market:

Among all the regions, North America is estimated to account for the largest share of the viral vector manufacturing market in the year 2023. Owing to the significance of key growth factors such as the increasing patient population suffering from genetic disorders, the rising incidence of cancer, sophisticated healthcare infrastructure, the presence of key players, and fast regulatory approval for new products, the market for viral vector manufacturing is expected to register significant growth in the region.

According to National Center on Birth Defects and Developmental Disabilities under the Centers for Disease Control and Prevention (CDC) 2022, sickle cell anemia affects about 100,000 Americans. As per the same source, Hemophilia A affects 1 in 5,000 male births and each year about 400 babies are born with hemophilia A in the United States.

The data published by CDC 2022 says that every year 57,000 men and 18,000 women get bladder cancer in the United States. As per Global Cancer Observatory 2020, about 80.6 thousand cases of bladder cancer were reported in the US in 2020 and by 2040 this number is expected to reach 122 thousand.

Additionally, various strategic activities on viral vector manufacturing in the United States are also anticipated to expand the viral vector manufacturing market during the given forecast period. For example, in October 2022, Kite, a Gilead Company announced that the US FDA has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.

Hence, the above-mentioned factors are going to increase the growth of the viral vector manufacturing market in the region.

Viral Vector Manufacturing Market Key Players:

Some of the key market players operating in the viral vector manufacturing market include Oxford Biomedica, Thermo Fisher Scientific Inc., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others.

Recent Developmental Activities in the Viral Vector Manufacturing Market:

In August 2022, Thermo Fisher Scientific, the world leader in serving science, expanded its cell and gene therapy capabilities with the opening of its new viral vector manufacturing facility in Plainville, Mass.

In October 2022, Merck, a leading science and technology company, announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint.

Key Takeaways from the Viral Vector Manufacturing Market Report Study

Market size analysis for current viral vector manufacturing market size (2023), and market forecast for 6 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the viral vector manufacturing market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global viral vector manufacturing market.

Various opportunities available for the other competitor in the viral vector manufacturing market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current viral vector manufacturing market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for viral vector manufacturing market growth in the coming future?

Target Audience who can be benefited from this Viral Vector Manufacturing Market Report Study

Viral Vector Manufacturing products providers

Research organizations and consulting companies

Viral Vector Manufacturing- related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in viral vector manufacturing

Various End-users who want to know more about the viral vector manufacturing market and the latest innovations and developments in the viral vector manufacturing market.

Frequently Asked Questions for the Viral Vector Manufacturing Market:

1. What are viral vectors?

Viral vectors are tools in molecular biology that have been designed and developed for the efficient and safe delivery of genetic materials into cells.

2. What is the market for global viral vector manufacturing?

The global viral vector manufacturing market was valued at USD 696.17 million in 2023, growing at a CAGR of 19.22% during the forecast period from 2024 to 2030 to reach USD 1,995.43 million by 2030.

3. What are the drivers for the global viral vector manufacturing market?

The growth of the viral vector manufacturing market is primarily being boosted by the increasing importance of viral vectors in gene and cell therapy, the increasing number of patients with genetic disorders, the rising incidence of cancer, and rising research and development activities related to viral vector manufacturing are contributing to the overall growth of the viral vector manufacturing market during the forecast period from 2024-2030.

4. Who are the key players operating in the global viral vector manufacturing market?

Some of the key market players operating in the viral vector manufacturing market include Oxford Biomedica, Thermo Fisher Scientific Inc., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others.

5. Which region has the highest share in the viral vector manufacturing market?

North America is expected to dominate the overall viral vector manufacturing market during the forecast period from 2024-2030. Factors such as the increasing patient population suffering from genetic disorders, the rising incidence of cancer, sophisticated healthcare infrastructure, the presence of key players, and the set-up of new viral vector manufacturing facilities, among others, are driving the growth of the viral vector manufacturing market in the region.